Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03232957 Completed - Clinical trials for Primary Osteoarthritis of Knee Nos

Intrathecal Morphine for Unilateral Total Knee Arthroplasty

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

This study evaluates postoperative numerical pain score and systemic opioid requirement within 48 hours for unilateral total knee arthroplasty. Comparing among 3 groups of intrathecal morphine; 0,50, 100 ug with multimodal analgesia.

NCT ID: NCT03232853 Completed - Clinical trials for Medical Errors : Drugs Errors During Anesthesia

E-learning to Prevent Drug Errors in Anesthesia

ELPdrug
Start date: July 31, 2017
Phase:
Study type: Observational

The purpose of this observational study is to assess the efficiency of an e-learning in order to put into practice some preventive measures to avoid medication errors during anesthesia.

NCT ID: NCT03232840 Completed - Clinical trials for Medical Errors : Wrong Site Surgery in Regional Anesthesia

E-learning to Prevent Wrong Site Surgery in Anesthesia

ELPSite
Start date: July 31, 2017
Phase:
Study type: Observational

The purpose of this observational study is to assess the efficiency of an e-learning in order to put into practice some preventive measures to avoid wrong site surgery during anesthesia.

NCT ID: NCT03232801 Completed - Sexual Dysfunction Clinical Trials

A Mindfulness-based Intervention for Older Women With Low Sexual Desire

Start date: October 8, 2020
Phase: N/A
Study type: Interventional

The overall aim of this research is to adapt and pilot test a multi-component, mindfulness-based behavioral intervention for women age 50 and older with low sexual desire.

NCT ID: NCT03232398 Completed - Clinical trials for Acute Myocardial Infarction

Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus

Start date: January 1, 2018
Phase: Phase 3
Study type: Interventional

Patients with acute ST-segment elevation myocardial infarction (STEMI) have an elevated risk of stroke, most of which are cardio-embolic in origin as a result of left ventricular (LV) thrombus formation. Anterior-wall location of a MI, in particular, can lead to the complications of LV aneurysm and/or thrombus, which some estimate occurs in approximately up to one-third of individuals within the first 2 weeks following an anterior MI. In the absence of anti coagulation, the risk of embolization in patients with a documented LV thrombus has been reported to be between 10 and 15 percent [3]. Although there are no randomized trials evaluating the efficacy of anticoagulation in patients with an LV thrombus after MI, observational studies provide substantial supporting evidence for the recommendation to anticoagulate patients with documented LV thrombus in order to reduce the risk of embolization. The observation that most events occur within the first three months from the MI forms the basis for the recommendation that anticoagulant therapy should be started early and continued for at least three to six months after myocardial infarction. Currently the practice guidelines recommend anticoagulation after MI only in certain settings such as the presence of LV thrombus or atrial fibrillation. To date there are no data on the use of novel oral anticoagulants (NOACS) for stroke prevention in the setting of LV thrombus after acute MI. The proposed aim of this randomized open label non inferiority clinical trial is to assess whether apixaban is as effective as VKA for the treatment of LV thrombus after acute ST segment elevation MI. Population: Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) 3 to 7 days post admission for acute ST-elevation MI Intervention: The patients will be randomly assigned to treatment with apixaban or s.c enoxaparin 1mg/Kg BID followed by dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months. The study Outcomes are the presence of LV thrombus as assessed be echo, major bleeding, and stroke or systemic embolism and death from any cause.

NCT ID: NCT03232203 Completed - Clinical trials for Severe Combined Immunodeficiency Due to ADA Deficiency

Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)

Start date: April 12, 2018
Phase:
Study type: Observational [Patient Registry]

STRIMVELIS is a medicinal product that restores adenosine deaminase (ADA) function in hematopoietic cell lineages, thereby preventing impaired immune function. STRIMVELIS is indicated for the treatment of patients with ADA- severe combined immunodeficiency (SCID), for whom suitable human leukocyte antigen (HLA)-matched related stem cell donor is not available. The objective of this study is to evaluate the effectiveness of routine and additional risk minimization measures by assessing the understanding of referring health care providers (HCPs) and parents/carers (hereby referred as participants) with regard to the specific risks associated with STRIMVELIS. In this cross-sectional study, surveys will be provided to referring HCPs and parents/carers of children approximately six months after treatment with STRIMVELIS. The study will recruit for approximately two years or until a maximum of 10 referring HCPs and 10 parents/carers have completed their respective surveys, whichever occurs first.

NCT ID: NCT03231943 Completed - HIV Infections Clinical Trials

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

Start date: September 19, 2017
Phase: Phase 1
Study type: Interventional

Human immuno deficiency virus 1 (HIV-1) infections continues to be a serious health threat throughout the world and development of medicines with new mechanism of action have an important role to play. GSK3640254 is a maturation inhibitor (MI) and can be effective in HIV-1 treatment. This randomized, 2-part, single and repeat increasing dose study will collect information on safety, tolerability and drug levels in the body of in healthy subjects for GSK3640254. The information collected in this study will help in further clinical development of GSK3640254, including a Phase IIA Proof of Concept (PoC) study in HIV-infected subjects. Approximately 16 healthy subjects will be randomized to receive single oral dose of GSK3640254 and placebo in Part 1 and approximately 56 healthy subjects will be randomized to receive repeat oral dose of GSK3640254 or placebo in Part 2. All doses will be given immediately after a moderate fat meal. Maximum duration of study participation will be approximately 12 weeks.

NCT ID: NCT03231839 Completed - Clinical trials for Type 2 Diabetes Mellitus

Nutritional Prevention of Diabetes Mellitus Type 2

NUPREDM
Start date: February 1, 2009
Phase: N/A
Study type: Interventional

This study investigates the influence of red meat and fibers on glucose metabolism and body fat composition in subjects at increased risk for type 2 diabetes.

NCT ID: NCT03231800 Completed - Clinical trials for Attention-Deficit Hyperactivity Disorder (ADHD)

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Start date: July 31, 2017
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.

NCT ID: NCT03231618 Completed - Clinical trials for Healthy and Overweight/ Obesity Males

The Intervention Study of Dietary Intake on Energy Expenditure

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

This study is a randomized crossover (2 × 3) dietary intervention. 40 male volunteers(20 normal weight, 20 overweight / obesity, no other serious disease or metabolic abnormalities) aged 18-45 years are required to take 3 kinds of isocaloric diets with different amounts of macronutrients: low-fat high-carbohydrate diets, low-carbohydrate high-fat diets and high-protein low-fat diets. The comparison is made within subject before and after the test meal. Each subject takes 6 meals of 3 kinds of diets on 6 separate days with a washout period between different diets. The study protocol was approved by the Ethics Committee of Shanghai Institutes for Biological Sciences and all participants provided written informed consents. The study is the first to investigate among overweight / obesity and normal weight in China to clarify: 1. the relationship between the proportion of macronutrients in diets and the energy metabolism efficiency. 2. the main genetic and non-genetic factors that impact individual energy metabolism, the characteristics of metabolic profiling and relative regulatory pathways.